Skip to main content

Advertisement

SpringerLink
Log in

Antibiotic consideration in bacterial vaginosis

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Bacterial vaginosis (BV) is a syndrome characterized by the loss of indigenous vaginal lactobacilli and massive polymicrobial anaerobic vaginal overgrowth of elusive etiology. Although progress has occurred in defining the composition of the vaginal microbiome using DNA amplifications, rapidly accumulating data have not resulted in therapeutic advantage. Treatment options remain limited and outcome often unsatisfactory, particularly regarding the frequent recurrence of symptomatic disease, leading to enormous frustration among patients and practitioners. This review does not address the important issues of transmission, diagnosis, and complications of BV, but focuses on antimicrobial activity of current drugs and their limitations in vitro and in vivo. Recognizing these limitations should allow for either development of new antibiotics or for innovative use of currently available drugs in new study protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Sobel JD: Bacterial vaginosis. Annu Rev Med 2000, 51:349–356.

    Article  CAS  PubMed  Google Scholar 

  2. Koumans EH, Sternberg M, Bruce C, et al.: The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007, 34:864–869.

    Article  PubMed  Google Scholar 

  3. Fredricks DN, Fiedler TL, Marrazzo JM: Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005, 353:1899–1911.

    Article  CAS  PubMed  Google Scholar 

  4. Ferris MJ, Masztal A, Aldridge KE, et al.: Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis 2004, 13:4–5.

    Google Scholar 

  5. Verhelst R, Verstraelen H, Claeys G, et al.: Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between Atopobium vaginae, Gardnerella vaginalis and bacterial vaginosis. BMC Microbiol 2004, 4:16.

    Article  PubMed  Google Scholar 

  6. Amsel R, Totten PA, Spiegel CA, et al.: Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983, 74:14–22.

    Article  CAS  PubMed  Google Scholar 

  7. Piot P, Van Dyck E, Godts P, Vanderheyden J: A placebo-controlled, double-blind comparison of tinidazole and triple sulfonamide cream for the treatment of nonspecific vaginitis. Am J Obstet Gynecol 1983, 147:85–89.

    CAS  PubMed  Google Scholar 

  8. Centers for Disease Control and Prevention, Workowski KA, Berman SM: Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006, 55(RR-11):1–94.

    Google Scholar 

  9. Oduyebo OO, Anorlu RI, Ogunsola FT: The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev 2009, 8:CD006055.

    Google Scholar 

  10. Greaves WL, Chungafung J, Morris B, et al.: Clindamycin versus metronidazole in the treatment of bacterial vaginosis. Obstet Gynecol 1988 72:799–802.

    CAS  PubMed  Google Scholar 

  11. Bradshaw CS, Morton AN, Hocking J, et al.: High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006, 193:1478–1486.

    Article  PubMed  Google Scholar 

  12. Hay P: Recurrent bacterial vaginosis. Curr Infect Dis Rep 2000, 2:506–512.

    Article  PubMed  Google Scholar 

  13. Senok A, Verstraebrn H, Temmerman M, Botta G: Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev 2006, 4:CD006289.

    Google Scholar 

  14. Lamp KC, Freeman CD, Klutman NE, Lacy MK: Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999, 36:353–373.

    Article  CAS  PubMed  Google Scholar 

  15. Davis B, Glover DD, Larsen B: Analysis of metronidazole penetration into vaginal fluid by reversed-phase high-performance liquid chromatography. Am J Obstet Gynecol 1984, 149:802–803.

    CAS  PubMed  Google Scholar 

  16. Fredricsson B, Hagström B, Nord CE, Rane A: Systemic concentrations of metronidazole and its main metabolites after intravenous oral and vaginal administration. Gynecol Obstet Invest 1987, 24:200–207.

    Article  CAS  PubMed  Google Scholar 

  17. Mattila J, Männistö PT, Mäntylä R, et al.: Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Chemother 1983, 23:721–725.

    CAS  PubMed  Google Scholar 

  18. Alper MM, Barwin BN, McLean WM, et al.: Systemic absorption of metronidazole by the vaginal route. Obstet Gynecol 1985, 65:781–784.

    CAS  PubMed  Google Scholar 

  19. Manthei RW, Feo LG, Stambaugh JE: Identification of the metabolites of metronidazole in the human vagina. Wiad Parazytol 1969, 15:403–405.

    CAS  PubMed  Google Scholar 

  20. Jones BM, Geary I, Alawattegama AB, et al.: In-vitro and in-vivo activity of metronidazole against Gardnerella vaginalis, Bacteroides spp. and Mobiluncus spp. in bacterial vaginosis. J Antimicrob Chemother 1985, 16:189–197.

    Article  CAS  PubMed  Google Scholar 

  21. Nagaraja P: Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosis. Indian J Med Microbiol 2008, 26:155–157.

    Article  CAS  PubMed  Google Scholar 

  22. Easmon CS, Ison CA, Kaye CM, et al.: Pharmacokinetics of metronidazole and its principal metabolites and their activity against Gardnerella vaginalis. Br J Vener Dis 1982, 58:246–249.

    CAS  PubMed  Google Scholar 

  23. Onderdonk AB, Louie TJ, Tally FP, Bartlett JG: Activity of metronidazole against Escherichia coli in experimental intra-abdominal sepsis. J Antimicrob Chemother 1979, 5:201–210.

    Article  CAS  PubMed  Google Scholar 

  24. De Backer E, Verhelst R, Verstraelen H, et al.: Antibiotic susceptibility of Atopobium vaginae. BMC Infect Dis 2006, 6:51.

    Article  PubMed  CAS  Google Scholar 

  25. De Backer E, Dubreuil L, Brauman M, et al.: In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis. Clin Microbiol Infect 2009 (Epub ahead of print).

  26. Swidsinski A, Mendling W, Loening-Baucke V, et al.: Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005, 106:1013–1023.

    PubMed  Google Scholar 

  27. Bradshaw CS, Tabrizi SN, Fairley CK, et al.: The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis 2006, 194:828–836.

    Article  CAS  PubMed  Google Scholar 

  28. Menard JP, Fenollar F, Henry M, et al.: Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clin Infect Dis 2008, 47:33–43.

    Article  CAS  PubMed  Google Scholar 

  29. Austin MN, Beigi RH, Meyn LA, Hillier SL: Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J Clin Microbiol 2005, 43:4492–4497.

    Article  CAS  PubMed  Google Scholar 

  30. Beigi RH, Austin MN, Meyn LA, et al.: Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004, 191:1124–1129.

    Article  PubMed  Google Scholar 

  31. Liu CY, Huang YT, Liao CH, et al.: Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008, 52:3161–3168.

    Article  CAS  PubMed  Google Scholar 

  32. Theron MM, Janse Van Rensburg MN, Chalkley LJ: Nitroimidazole resistance genes (nimB) in anaerobic Gram-positive cocci (previously Peptostreptococcus spp.). J Antimicrob Chemother 2004, 54:240–242.

    Article  CAS  PubMed  Google Scholar 

  33. Puapermpoonsiri S, Watanabe K, Kato N, Ueno K: In vitro activities of 10 antimicrobial agents against bacterial vaginosis-associated anaerobic isolates from pregnant Japanese and Thai women. Antimicrob Agents Chemother 1997, 41:2297–2299.

    CAS  PubMed  Google Scholar 

  34. Ferris DG, Litaker MS, Woodward L, et al.: Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract 1995, 41:443–449.

    CAS  PubMed  Google Scholar 

  35. Sobel JD, Ferris D, Schwebke J, et al.: Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006, 194:1283–1289.

    Article  CAS  PubMed  Google Scholar 

  36. Reichman O, Akins R, Sobel JD: Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 2009 (Epub ahead of print).

  37. Sanchez S, Garcia PJ, Thomas KK, et al.: Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol 2004, 191:1898–1906.

    Article  CAS  PubMed  Google Scholar 

  38. Jones BM, Geary I, Lee ME, Duerden BI: Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections. Antimicrob Agents Chemother 1989, 33:970–972.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Harper University Hospital, 3990 John R Street, Detroit, MI, 48201, USA

    Jack D. Sobel

Authors
  1. Jack D. Sobel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jack D. Sobel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sobel, J.D. Antibiotic consideration in bacterial vaginosis. Curr Infect Dis Rep 11, 471–475 (2009). https://doi.org/10.1007/s11908-009-0068-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-009-0068-5

Keywords

Search

Navigation